Array Biopharma to Report Financial Results for the First Quarter of Fiscal 2018 On October 31, 2017

BOULDER, Colo., Oct. 24, 2017 /PRNewswire/ -- Array BioPharma, Inc. will report financial results for the first quarter of fiscal 2018 and hold a conference call to discuss those results on Tuesday, October 31, 2017. Ron Squarer, Chief Executive Officer, will lead the call.

    Date:                  Tuesday, October 31, 2017

    Time:                  9:00 a.m. Eastern Time

    Toll-Free:             (844) 464-3927

    Toll:                  (765) 507-2598

    Pass Code:                                94698561

Webcast, including Replay and Conference Call Slides:
https://edge.media-server.com/m6/p/hcxcet4b

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

    CONTACT:                          Tricia Haugeto

                                      Array BioPharma Inc.

                                      (303) 386-1193

                                      thaugeto@arraybiopharma.com

View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-first-quarter-of-fiscal-2018-on-october-31-2017-300541497.html

SOURCE Array BioPharma Inc.